Omar Abdel-Wahab

Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution.

Immunotherapy of surgical malignancies.

Modulation of resistance to regional chemotherapy in the extremity melanoma model.

In-transit melanoma: the role of alkylating-agent resistance in regional therapy.

The role of hyperthermia in regional alkylating agent chemotherapy.

Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses.

Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity.

Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.

Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature.

Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities.

An 87-year-old woman with respiratory distress and alveolar hemorrhage after transfusion.

Functional evaluation of the grafted wall with porcine-derived small intestinal submucosa (SIS) to a stomach defect in rats.

Primary myelofibrosis: update on definition, pathogenesis, and treatment.

Warfarin-induced skin necrosis in a patient with heparin-induced thrombocytopenia: two diseases or one?

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms.

Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Metabolism and the leukemic stem cell.

Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera.

Recent advances in the treatment of acute myeloid leukemia.

The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia.

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.

A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition.

Genetics of the myeloproliferative neoplasms.

JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation.

Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q.

A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia.

Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML.

Clinical effect of point mutations in myelodysplastic syndromes.

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy.

TET family proteins and their role in stem cell differentiation and transformation.

FISHing for TET2: Utility of FISH for TET2 deletions detection in clinical samples.

Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen.

The spliceosome as an indicted conspirator in myeloid malignancies.

Clinical implications of novel mutations in epigenetic modifiers in AML.

Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.

Nuclear JAK2.

Molecular alterations underlying eosinophilic and mast cell malignancies.

IDH mutation impairs histone demethylation and results in a block to cell differentiation.

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.

Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.

Molecular genetics of acute myeloid leukemia: clinical implications and opportunities for integrating genomics into clinical practice.

2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels.

Refining the prognostic importance of the diversity of FLT3 internal tandem duplications.

Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.

Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.

Loss of the tumor suppressor BAP1 causes myeloid transformation.

ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.

The role of mutations in epigenetic regulators in myeloid malignancies.

Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.

Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.

Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms.

Epigenetic alterations in hematopoietic malignancies.

Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.

Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis.

Progression of RAS-mutant leukemia during RAF inhibitor treatment.

Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemia.

Interpreting new molecular genetics in myelodysplastic syndromes.

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.

The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.

HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders.

Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.

Notch pathway activation targets AML-initiating cell homeostasis and differentiation.

Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia.

Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression.

GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.

Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.

EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

Importance of genetics in the clinical management of chronic myelomonocytic leukemia.

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.

Detection of an NRAS mutation in Erdheim-Chester disease.

Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.

Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.

The importance of subclonal genetic events in MDS.

Focus on the epigenome in the myeloproliferative neoplasms.

Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations.

D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.

Recent discoveries in molecular characterization of acute myeloid leukemia.

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.

Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.

Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.

Hematopoietic Stem Cell Origin of BRAFV600E Mutations in Hairy Cell Leukemia.

Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myeloid leukemia.

Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.